Sinocare

Sinocare FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Sinocare (300298.SZ) as of Oct 16, 2026 is 438.51 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 136.26 % — a change of 221.81% (higher).

FCF Conversion

438.51 %

YoY

221.81%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Sinocare is 2025 438.51 % . FCF Conversion Rate (FCF/EBITDA) of Sinocare was 2024 136.26 % . It decreases by 221.81% higher compared to the previous year.

The Sinocare FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
24.76 CNY
Jan 1, 2019
40.23 CNY
Jan 1, 2020
122.58 CNY
Jan 1, 2021
70.87 CNY
Jan 1, 2022
36.55 CNY
Jan 1, 2023
136.62 CNY
Jan 1, 2024
136.26 CNY
Jan 1, 2025
438.51 CNY
The Sinocare FCF Conversion history
YEARFCF ConversionYoY
438.51 %+221.81%
136.26 %-0.26%
136.62 %+273.78%
36.55 %-48.43%
70.87 %-42.18%
122.58 %+204.70%
40.23 %+62.46%
24.76 %-56.01%
56.29 %-56.17%
128.43 %+193.86%
43.70 %+2.89%
42.47 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sinocare Stock analysis

What does Sinocare do? Sinocare Inc, listed on the Shenzhen Stock Exchange under ticker 300298.SZ, operates as a healthcare company headquartered in Changsha, China. The company went public on March 19, 2012, and currently employs 3,756 full-time staff. Sinocare focuses on the development, production, and sale of rapid detection products for chronic diseases, particularly in the field of diabetes management. Its primary offerings include micro blood glucose monitoring systems, such as blood glucose testing devices and associated test strips, as well as mobile blood glucose monitoring instruments. The company also provides diabetes management information systems to support patient care and data tracking. Sinocare distributes its products both domestically within China and internationally under the brand name SANNUO. The company's website is https://www.sinocare.com/. Sinocare's business model centers on providing accessible and reliable diagnostic tools for chronic disease management, with a strong emphasis on diabetes-related products. The company operates within the healthcare sector, specifically targeting the health care industry segment. Its operations are based in Changsha, Hunan Province, and it serves both local and global markets through its branded products. Sinocare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sinocare stock

FCF Conversion Rate (FCF/EBITDA) of Sinocare is 438.51 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Sinocare changed from 136.26 % to 438.51 %, representing a 221.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Sinocare since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Sinocare with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Sinocare

All Key Metrics — Sinocare